Advancing patient care through molecular diagnostic testing

Interpace Diagnostics develops molecular diagnostic tests. You can be assured that all of the molecular tests we offer are driven by rigorous, validated science.

We power the future of molecular diagnostics, delivering cutting-edge and much-needed mutational analysis that helps risk-stratify for thyroid, pancreatic, and other cancers to better inform treatment decisions. The unique molecular diagnostic tests we offer enable healthcare providers to avoid unnecessary surgeries and better assess the risk of cancer progression in their patients.

Our molecular diagnostic tests provide unparalleled accuracy and clarity to improve outcomes in patients facing a cancer diagnosis.

Interpace Diagnostics Molecular Tests

Thyroid

ThyGenX ThyraMIR logos

ThyGenX® Thyroid Oncogene Panel and ThyraMIR™ Thyroid miRNA Classifier molecular testing that aids in the diagnosis of thyroid nodules by identifying genetic alterations associated with thyroid cancer

I am a physician
I am a patient

Pancreas

PancraGen logo

PancraGEN™ is a unique, DNA-based, integrated molecular pathology test that assesses the risk of cancer in pancreatic cysts, helping you to optimally manage each individual patient.

I am a physician
I am a patient

In the Pipeline: Looking Toward the Future of Molecular Diagnostics

We constantly explore areas for the future, invest in research and partnerships, seek opportunities to expand our molecular diagnostics capabilities and serve additional unmet needs in molecular diagnostic testing.

Barrett’s Esophagus

Molecular diagnostic test to determine the risk of progressing to esophageal cancer in patients with Barrett’s Esophagus

BarreGEN Logo

Pancreatobiliary Cancer

Late-stage development of a test to assess pancreatobiliary cancer risk by testing tissue taken from biliary stricture brushings

Announcements

Interpace Diagnostics Invited to Present Data at Upcoming American Thyroid Association (ATA) Annual Meeting

PARSIPPANY, N.J., Sept. 12, 2016 /PRNewswire/ -- Interpace Diagnostics Group (IDXG), a company that provides clinically useful molecular diagnostic tests and pathology services for evaluating risk of cancer by leveraging the latest technology in personalized medicine [...]

Interpace Diagnostics Reports Record Revenue and Cash Collections for the 2016 Second Quarter

- Net Revenue Grows 60% Year over Year and 19% Sequentially - Cash Collection for Q2 Exceeds $3.3 million - Loss from Continuing Operations Declines 59% PARSIPPANY, N.J., Aug. 16, 2016 /PRNewswire/ -- Interpace Diagnostics [...]

Interpace’s Greg Richard to present at the 8th Annual Next Generation Dx Summit, August 23-26

Interpace is pleased to announce that Greg Richard, our Sr. Vice President of Commercial Services, will be a featured speaker at the upcoming Next Generation Dx Summit being held in Washington,  D.C. Thursday, August 25th.  [...]

View All

Updates

  • DrLorenVideoThumb

Managing Patients With Pancreatic Cystic Lesions

David Loren, MD, Thomas Jefferson University, shares data on the molecular test, PancraGen, which helps identify false negative cases that could be missed by first-line tests like imaging, cytology and fluid chemistry. […]